Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

Right arrow Help viewing high resolution images
Right arrow Return to article

Please click here to obtain permission to reproduce this image.

Click on image to view larger version.



Figure 1 Mechanism of action of clopidogrel. Clopidogrel competitively and irreversibly inhibits the adenosine diphosphate (ADP) P2Y12 receptor; ADP binds to the P2Y1 receptor to induce change in platelet shape and a weak and transient platelet aggregation. The binding of ADP to its Gi-coupled P2Y12 receptor liberates the Gi protein subunits {alpha}Gi and ß{gamma}. The subunit {alpha}Gi leads to the inhibition of adenylyl cyclase (AC), which, in turn, lowers the cyclic adenosine monophosphate (cAMP) level. This inhibits the cAMP-mediated phosphorylation of vasodilator-stimulated phosphoprotein (VASP) (VASP-P), which is known to be closely related to the inhibition of glyprotein IIb/IIIa receptor activation. The subunit ß{gamma} activates the phosphatidylinositol 3-kinase (PI3K), which potentiates dense- and {alpha}-granule secretion. Multiple arrows within a given pathway indicate that intermediate steps may be involved. Dotted arrows indicate inhibition, whereas solid arrows represent activation. CYP450 = cytochrome P450; PGE1 = prostaglandin E1; PKA = protein kinase activation; PLC = phospholipase C.





Right arrow Return to article

 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement